All News

Article

The Great Debate – Who Really Won?

Michael Putman, MD, MSCI Oct 28, 2025

My favorite session at ACR Convergence is often the “Great Debate.” The debate this year also evaluated one of my favorite topics – ultrasound in giant cell arteritis (GCA). More specifically, it asked the question of whether biopsy or ultrasound should be the preferred modality for diagnosing GCA.

Article

Accelerated Aging in Rheumatic Disease: From Biology to Lifestyle Intervention

Jiha Lee, MD Oct 28, 2025

At ACR 2025, the session “27M02: Nutrition for Rheumatic Disease: Where Aging Biology, Sarcopenia, and Diet Intersect” invited the audience to view rheumatic disease through the lens of biological aging and to consider how nutrition and exercise can serve as integrative lifestyle interventions.

#2702 @ClevelandClinic Vascular ultrasound (VUS) for suspected GCA showed excellent specificity (100%) but low sensitivity (21%) compared with 6m confirmed diagnosis. Fair agreement with TAB (κ=0.64). Findings highlight need for standardised VUS protocols in US. @RheumNow #ACR25 https://t.co/LRFpFBnWWz

https://x.com/DrMiniDey/status/1983588138829467855/photo/1

Older Adults Underrepresented in RCTs Drs. Jiha Lee and Sebastian Sattui discuss abstract 1072, "Inclusion of Older Adults in Pharmacologic Randomized Controlled Clinical Trials of Autoimmune Rheumatic Diseases: A Systematic Review," presented at #ACR25 https://t.co/uzSPH5RbjM https://t.co/94Vw6qUOIL

Older Adults Underrepresented in RCTs | RheumNow

#ACR25 Abstr#2697 H2H RCT of Tacrolimus + GC vs MMF + GC in #lupus Nephritis in Asia for Induction-Maintenance showed similar efficacy. Different side effects: AKI more in TAC, low WCC & infections in MMF. Informative for services with no access to biologics/Voclosporin @RheumNow https://t.co/V4uWhuqjjW

https://x.com/Yuz6Yusof/status/1983578834315157825/photo/1

Impact on handedness in PsA disease activity and structural damage: a question that often comes in my practice Comments on Abstract #1415 presented at #ACR25 https://t.co/GilOFvXajJ @RheumNow

The Upper Hand in PsA? Not the Dominant One | RheumNow

“We’ve got to do better for our patients with GCA” - Laura Coates, doing the #ACR25 meeting review She told us she is speaking about diseases outside her comfort zone but she is bang on. As she said: not good enough real world all the people not on steroid-sparing Rx @RheumNow https://t.co/4WiEORwPgI

https://x.com/drdavidliew/status/1983554079453483409/photo/1

Nice to see a Dietary intervention study in the "Top Abstracts That Will Change My Practice in the Near Future" by L. Coates for Year in Preview Small RCT but fibres significantly improve response to treatment in the MTX treated RA group with a mean reduction of DAS28 of https://t.co/vMeIAK1P5u

https://x.com/AurelieRheumo/status/1983553385505726631/photo/1

RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.

In a U.S. axSpA cohort (n=4,799), women had a 24% higher adjusted risk of TNFi discontinuation vs men especially under age 65. No sex differences seen for IL-17i or JAKi, though sample sizes were small. Highlights need for sex-informed treatment strategies. Abstract#2634 https://t.co/58Dw3nFCsf

https://x.com/synovialjoints/status/1983549391203119443/photo/1

🎥 LIVE from #ACR25 Join us daily at 5 PM CST for RheumNow’s ACR Recap Live - Your must-watch debrief of the day’s biggest breakthroughs, hot abstracts, and real-time clinical takeaways. Streaming on YouTube Live, Facebook Live, X-Live & LinkedIn Live. Save the time. Be part of https://t.co/beh3bEL8fs

RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.

Sex differences in 💊 d/c in axSpA from the RISE registry 🔅Females - ⬆️discontinuation risks for TNFi 🔅No sex differences seen in dc risks for IL17i and JAKis 🔅Young females discontinued faster than males Gender diff in SpA can guide tx decisions #ACR25 @RheumNow Abs2634 https://t.co/kcXfZrU4zI

What a conference! Thanks to all those who stopped by! #ACR25 https://t.co/UMAqnPdK4t

CDAI appropriately guided therapy escalation in RA, but not for everyone. Treatment adjustments were less likely in pts with public or no insurance. Even data-driven care can fall short when access barriers persist. @RheumNow #ACR25 Abstract#2616

RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is selected by RheumNow and its faculty.

Is AI Smarter than a Doctor? Dr. Janet Pope reviews key takeaways from the session, "Artificial Intelligence in Medical Education: From Theory to Practice," at #ACR25. https://t.co/F6KEYAWi75 https://t.co/m57asdLGrn

Is AI Smarter than a Doctor? | RheumNow

@RheumNow Plus a heap more biosimilars have broken through in the US in the last year. It feels the biosimilar era is now here stateside, too. #ACR25 FDA Update @RheumNow https://t.co/9RiyhbKXU4

https://x.com/drdavidliew/status/1983238835724247300/photo/1

@US_FDA rheumatology approvals, 2025 #ACR25 @RheumNow https://t.co/uVLWqBx45m

https://x.com/drdavidliew/status/1983234312305824068/photo/1

Can a Fitbit track RA? This Japanese clinic is using Fitbit data and have seen it correlate with CDAI across their RA clinic. Maybe instead of asking about our patients mobility and sleep, we should be measuring it? #ACR25 ABST2253 @RheumNow https://t.co/rg2SKgn7K2

https://x.com/drdavidliew/status/1983227402605211728/photo/1

Topics

All News

The Great Debate – Who Really Won?

Accelerated Aging in Rheumatic Disease: From Biology to Lifestyle Intervention

Do you get our email newsletter?